Keros Therapeutics (NASDAQ:KROS) Price Target Lowered to $20.00 at Wells Fargo & Company

Keros Therapeutics (NASDAQ:KROS) had its target price decreased by Wells Fargo & Company from $23.00 to $20.00 in a research note published on Thursday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

Several other research firms also recently issued reports on KROS. Weiss Ratings reiterated a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday, December 29th. Wedbush raised their price objective on Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, November 6th. Zacks Research cut Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Bank of America increased their price target on Keros Therapeutics from $18.00 to $19.00 and gave the company a “neutral” rating in a report on Friday, November 28th. Finally, Oppenheimer restated an “outperform” rating and issued a $27.00 price objective (up from $23.00) on shares of Keros Therapeutics in a research note on Wednesday, November 12th. Five analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Hold” and an average target price of $21.86.

Keros Therapeutics Stock Down 15.0%

KROS stock opened at $11.71 on Thursday. The firm has a 50 day moving average of $17.60 and a two-hundred day moving average of $17.06. Keros Therapeutics has a 12 month low of $9.12 and a 12 month high of $22.55. The company has a market capitalization of $356.80 million, a price-to-earnings ratio of 6.43 and a beta of 0.87.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, March 4th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.37). The business had revenue of $0.39 million during the quarter, compared to analyst estimates of $3.66 million. Keros Therapeutics had a net margin of 35.65% and a return on equity of 12.20%. The firm’s revenue for the quarter was down 87.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.14) EPS. On average, research analysts expect that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd grew its stake in shares of Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after acquiring an additional 1,166 shares during the last quarter. Invesco Ltd. boosted its holdings in Keros Therapeutics by 16.6% in the 4th quarter. Invesco Ltd. now owns 87,428 shares of the company’s stock valued at $1,780,000 after purchasing an additional 12,449 shares during the period. Empowered Funds LLC bought a new stake in Keros Therapeutics in the 4th quarter valued at $1,223,000. XTX Topco Ltd acquired a new stake in Keros Therapeutics in the 4th quarter worth $212,000. Finally, VARCOV Co. bought a new position in shares of Keros Therapeutics during the 4th quarter worth about $261,000. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.